BL-8040: Additional Phase IIa data

Data from 39 patients with relapsed or refractory AML in an open-label, U.S. and Israeli Phase IIa trial showed that once-daily 1-2 mg/kg subcutaneous BL-8040 as monotherapy on days 1 and 2 followed b...